UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
Kronos Bio, Inc.
(Name of Subject Company)
Kronos Bio, Inc.
(Name of Persons Filing Statement)
COMMON STOCK, PAR VALUE $ 0.001 PER SHARE
(Title of Class of Securities)
62857M105
(CUSIP Number of Class of Securities)
Deborah Knobelman
301 Binney Street, 2nd Floor East
Cambridge, MA 02142
(650) 781-5200
With copies to:
Michael R. Patrone, Esq.
Amanada J. Gill, Esq.
Goodwin Procter LLP
New York Times Bldg
620 8th Ave
New York, NY 10018
(212) 813-8800
(Name, address, and telephone numbers of person authorized to receive notices and communications
on behalf of the persons filing statement)
| ☒ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
The information set forth under Items 1.01, 8.01 and 9.01 of the Current Report on Form 8-K filed by Kronos Bio, Inc. on May 1, 2025 (including all exhibits attached thereto) is incorporated herein by reference.